Metsera Inc., a clinical-stage biopharmaceutical company, has announced progress in its ongoing clinical programs targeting obesity and metabolic diseases. The company is advancing its MET-097i program, a fully biased, monthly injectable GLP-1 receptor agonist, with the release of VESPER-1 and interim VESPER-3 data anticipated in September 2025. These results will contribute to the development of Phase 3 trials slated for late 2025. Additionally, Metsera's MET-233i, a once-monthly amylin analog, has shown promising Phase 1 results with an 8.4% weight loss over five weeks and a 19-day half-life. Further 12-week monotherapy and co-administration data are expected by the end of 2025 or early 2026. Metsera's pipeline also includes oral peptide programs, with four-week data for selected leads expected in late 2025. The company maintains a robust financial position, with $530.9 million in cash and cash equivalents, ensuring operational runway into 2027.